Estimation of minimally important differences and responder definitions for EORTC QLQ‐MY20 scores in multiple myeloma patients

Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients

(2019) Thierry Facon et al.   BLOOD

Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol

(2018) Zebedee Jammbe Musoro et al.   BMJ Open

Defining the minimally clinically important difference of the SF-36 physical function subscale for paediatric CFS/ME: triangulation using three different methods

(2018) Amberly Brigden et al.   Health and Quality of Life Outcomes

Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review

(2018) Ahmad Ousmen et al.   Health and Quality of Life Outcomes

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment

(2017) X Leleu et al.   Blood Cancer Journal

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach

(2016) Heather L. Gelhorn et al.   CLINICAL THERAPEUTICS

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

(2016) A. Keith Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Using ROC Curves to Choose Minimally Important Change Thresholds when Sensitivity and Specificity Are Valued Equally: The Forgotten Lesson of Pythagoras. Theoretical Considerations and an Example Application of Change in Health Status

(2014) Robert Froud et al.   PLoS One

Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer

(2013) Gillian Bedard et al.   Asia-Pacific Journal of Clinical Oncology

Review of health-related quality of life data in multiple myeloma patients treated with novel agents

(2013) P Sonneveld et al.   LEUKEMIA

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

(2012) M. A. Dimopoulos et al.   HAEMATOLOGICA

Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients

(2011) Kathleen J. Yost et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2—Assessing Respondent Understanding

(2011) Donald L. Patrick et al.   VALUE IN HEALTH

Responder Analyses—A PhRMA Position Paper

(2011) Tom Uryniak et al.   Statistics in Biopharmaceutical Research

A point of minimal important difference (MID): a critique of terminology and methods

(2011) Madeleine T King   Expert Review of Pharmacoeconomics & Outcomes Research

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

(2010) John T. Maringwa et al.   SUPPORTIVE CARE IN CANCER

What changes in health-related quality of life matter to multiple myeloma patients? A prospective study

(2009) Ann K. Kvam et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Three ways to quantify uncertainty in individually applied “minimally important change” values

(2009) Henrica C.W. de Vet et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes

(2007) Dennis Revicki et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY